OPA1 overexpression ameliorates mitochondrial cristae remodeling, mitochondrial dysfunction, and neuronal apoptosis in prion diseases

Wei Wu1,2, Deming Zhao1, Syed Zahid Ali Shah3, Xixi Zhang1, Mengyu Lai1, Dongming Yang1, Xiaoqian Wu1, Zhiling Guan1, Jie Li1, Huafen Zhao1, Wen Li1, Hongli Gao1, Xiangmei Zhou1, Jian Qiao2 and Lifeng Yang1

Abstract
Prion diseases caused by the cellular prion protein (PrPc) conversion into a misfolded isoform (PrPSc) are associated with multiple mitochondrial damages. We previously reported mitochondrial dynamic abnormalities and cell death in prion diseases via modulation of a variety of factors. Optic atrophy 1 (OPA1) is one of the factors that control mitochondrial fusion, mitochondrial DNA (mtDNA) maintenance, bioenergetics, and cristae integrity. In this study, we observed downregulation of OPA1 in prion disease models in vitro and in vivo, mitochondria structure damage and dysfunction, loss of mtDNA, and neuronal apoptosis. Similar mitochondria findings were seen in OPA1-silenced uninfected primary neurons. Overexpression of OPA1 not only alleviated prion-induced mitochondrial network fragmentation and mtDNA loss, decrease in intracellular ATP, increase in ADP/ATP ratio, and decrease in mitochondrial membrane potential but also protected neurons from apoptosis by suppressing the release of cytochrome c from mitochondria to cytosol and activation of the apoptotic factor, caspase 3. Our results demonstrated that overexpression of OPA1 alleviates prion-associated mitochondrial network fragmentation and cristae remodeling, mitochondrial dysfunction, mtDNA depletion, and neuronal apoptosis, suggesting that OPA1 may be a novel and effective therapeutic target for prion diseases.

Introduction
Prion diseases are transmissible fatal neurodegenerative disorders, which occur in humans (e.g., Creutzfeldt–Jakob Disease [CJD], Kuru, and so on) and other mammalian species (bovine spongiform encephalopathy [BSE] in cattle, scrapie in sheep, chronic wasting disease [CWD] in cervidae). Prion diseases are caused by accumulation of protease-resistant misfolded form (PrPSc) rich in beta-sheet structure, mainly consisting of alpha-helical structure. Typical lesions of prion diseases are spongiform vacuolation, proliferation of astrocytes, and neuronal loss in the central nervous system (CNS). The neurotoxic PrP fragment 106–126 (PrP106–126) has similar chemical and pathogenic properties to PrPSc, including high beta-sheet structure and proteinase K resistance, and causes neuronal apoptosis and induces proliferation of astrocytes. Consequently, PrP106–126 is used as a model peptide of PrPSc for the study of prion diseases.

Mitochondrial damage and dysfunction is a common feature in prion diseases and other neurodegenerative conditions. Abnormalities of mitochondrial dynamics occur in the early stage of neurodegenerative diseases. The mitochondrion is a dynamic organelle and constantly divides and fuses to maintain sufficient energy to the cell, which is critical to cell viability and function. The
protein machinery that controls mitochondrial dynamics is a set of large dynamin-related GTPase proteins. The dynamin-like protein 1 (DLP1) is a key player in mitochondrial fission process; during fission, cytosolic DLP1 translocates to mitochondrial outer membrane by receptor proteins, such as fission 1 (Fis 1) and mitochondria fission factor (Mff)\textsuperscript{11–13}. The mitofusins 1/2 (MNF1 and MFN2) are required for fusion of the outer mitochondrial membrane; MFN2 is considered to play a major regulatory role and MFN1 tethers two juxtaposed organelle\textsuperscript{14,15}. Optic atrophy 1 (OPA1) localizes to the inner mitochondrial membrane (IMM) and, together with MFN1, induces mitochondrial fusion\textsuperscript{16}, maintains mitochondrial DNA (mtDNA) replication and distribution and also stabilizes bioenergetics efficiency\textsuperscript{17,18}. In addition, OPA1 also controls apoptosis through cristae remodeling and cytochrome c release independently from mitochondrial fusion\textsuperscript{19,20}.

In a previous study, we reported mitochondrial fragmentation and dysfunction in prion diseases, and inhibition of DLP1 markedly ameliorates PrP\textsuperscript{106–126}-induced mitochondrial dysfunction and neuronal death. In this study, we investigated the role of OPA1 in prion-induced abnormalities of mitochondrial dynamics and neuronal apoptosis. Our research shows that the protein level of OPA1 is dramatically downregulated in in vitro and in vivo models of prion diseases, and OPA1 overexpression alleviated PrP\textsuperscript{106–126}-induced mitochondrial cristae collapse, mtDNA depletion, mitochondrial dysfunction, and neuronal apoptosis. Our results indicate that OPA1 may be another potential therapeutic target of prion diseases.

**Materials and methods**

**Animal ethics approval**

All animal experiments were conducted according to the guidelines of Beijing Municipality on the Review of Welfare and Ethics of Laboratory Animals and approved by the Beijing Municipality Administration Office of Laboratory Animals.

**Mouse prion diseases model**

Female C57Bl/6 mice aged 4–6 weeks (n = 20) were randomly divided into two groups. One group (n = 10) was inoculated intracerebrally with the RML scrapie agent, and the other group (n = 10) was used as age-matched controls. The mice were sacrificed when the animals developed late-stage prion disease based on clinical signs.

**Primary cortical neuron culture**

Cerebral cortex neurons were isolated from a 1-day-old neonatal rat as described previously\textsuperscript{21}. Briefly, cells were dissociated after digestion with Dulbecco’s modified Eagle’s medium (DMEM) containing 2 mg/ml papain (Invitrogen, Carlsbad, CA, USA) and 50 mg/ml DNase (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37 °C. The dissociated cells were plated at a density of 5 × 10\textsuperscript{5} cells per well and cultured in Neurobasal-A Medium (Invitrogen, USA) containing 2% serum-free B27 supplement (Invitrogen, USA) and 0.5% Penicillin–Streptomycin (Gibco, USA). After 2 days, 10 μM cytarabine (Sigma, USA) were added to control glial cell growth. Then half of the medium was replaced by fresh medium every 2 days. Experimental treatments were performed after culture for 7 days.

**Plasmids and transfection**

OPA1 small interfering RNA (siRNA; sequence: 5’- GUUAUCAGUCUGGCCAGGT-3’) was obtained from Synbio Technologies, Suzhou. The pCAG-OPA1 plasmid was obtained from Vitalstar Biotechnology, Beijing. Primary neurons were transfected with siRNA or pCAG-OPA1 plasmid using the Lipofectamine 3000 reagent (Invitrogen, USA) in Opti-MEM (Invitrogen, USA) for 48 h following the manufacturer’s instructions.

**Prion protein peptide**

PrP peptide PrP\textsuperscript{106–126} (sequence: KTNMKHMA-GAAAAGAVVGGLG) of 98% purity was synthesized by Sangon Bio-Tech (Beijing, China). The peptide was dissolved in 0.1 M phosphate-buffered saline (PBS) to a concentration of 1 mM and allowed to aggregate at 4 °C for 24 h. Experiments were conducted with the final peptide concentration of 150 μM.

**Mitochondrial and cytoplasmic protein isolation**

Mitochondrial and cytoplasmic proteins were extracted from brain tissue or neuron cell culture using a Qproteome Mitochondria Isolation Kit (Qiagen, Germany). Cells or freshly excised tissues were homogenized with a lysis buffer (Qiagen, Germany) supplemented with a Protease Inhibitor (Qiagen, Germany) and centrifuged at 1000 × g for 10 min at 4 °C. The supernatant contains mainly cytosolic proteins and was frozen for western blotting for cytosolic cytochrome c. The pellet was resuspended in an ice-cold disruption buffer (Qiagen, Germany) and centrifuged at 10000 × g for 10 min at 4 °C. The supernatant was transferred to a 1.5-ml tube and centrifuged at 6000 × g for 10 min at 4 °C. The resulting mitochondrial pellet was washed with a mitochondria storage buffer (Qiagen, Germany) and centrifuged at 6000 × g for 20 min at 4 °C. The mitochondrial pellet was resuspended in RIPA lysis buffer (Beyotime, China) and then frozen for western blotting.

**Western blotting**

Specific proteins expressed in the mouse brain and neuron cell cultures were determined by western blotting
using specific antibodies. Proteins (40 μg) were separated on 10% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and then transferred onto a nitrocellulose membrane. Nonspecific binding sites were blocked using 5% fat-free dried milk in 1× TBST at 37°C for 1 h. The membrane was incubated at 4°C overnight with individual primary antibodies, including rabbit anti-OPA1 (Cell Signaling Technology, USA), rabbit anti-MFN1 (Proteintech, USA), mouse anti-MFN2 (Abcam, USA), rabbit anti-cytochrome c (Cell Signaling Technology, USA), rabbit anti-cleaved caspase 3 (Cell Signaling Technology, USA), rabbit anti-β-actin (Proteintech, USA), mouse anti-MFN2 (Abcam, USA), OPAL (Cell Signaling Technology, USA), rabbit anti-VDAC (Cell Signaling Technology, USA), mouse anti-OPA1 (Abcam, USA) before treatment with PrP106–126 or control peptide. Fluorescence images of mitochondria were acquired using an Olympus confocal microscope. Measurement of mitochondrial length was performed using Image J (National Institutes of Health, USA).

**Immunofluorescence microscopy**

Primary neuronal cells were seeded on 24-well cover slips and then transfected with Mito-GFP (Clontech, USA) before treatment with PrP106–126 or control peptide. Fluorescence images of mitochondria were acquired using an Olympus confocal microscope. Measurement of mitochondrial length was performed using Image J (National Institutes of Health, USA).

**Transmission electron microscopy**

Brain samples of approximately 2 × 2 × 2 mm³ in size and pellets of cultured primary neuron cells were fixed in ice-cold 5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) at 4°C. The tissue or cells fixed in glutaraldehyde were rinsed with sodium cacodylate buffer and then further fixed in 1% OsO4 in 0.1 M sodium cacodylate buffer on ice for 2 h before dehydration with acetone. The tissue and cell pellets were embedded in resin before polymerization at 60°C for 48 h. Ultrathin sections (70 nm) were mounted onto copper grids and counterstained with 4% uranyl acetate and lead citrate before observation under a transmission electron microscope (JEM-1230, Japan) operating at 80 kV.

**Cell viability assay**

Viability of neuron cells in response to peptide treatment was evaluated using the Cell Counting Kit-8 (CCK-8) assay (Beyotime, China). Briefly, the CCK-8 solution was added to primary cultures of rat cortical neurons and incubated for 1 h at 37°C and 5% CO₂. The absorbance of the samples was obtained at 450 nm using a microplate reader (ThermoFisher, USA). The cell viability of treated cultures was expressed as the percentage of the control culture.

**Statistical analysis**

All assays were repeated at least three times. Data were expressed as means ± SEM. All comparisons for parametric data were analyzed using Student’s t test or one-way analysis of variance followed by post hoc Tukey’s test using the SPSS software (version 13.0: SPSS Inc., Chicago, IL, USA), GraphPad Prism 5 software (La Jolla, CA, USA), and Image J (National Institutes of Health, USA). P < 0.05 was considered statistically significant.

**Results**

OPA1 is downregulated in prion disease models in vivo and in vitro

We previously reported abnormalities of mitochondrial morphology and function in prion diseases like other
neurodegenerative diseases and increased mitochondrial DLP1 in both in vitro and in vivo prion models. To search for other mitochondrial fusion proteins involved in mitochondrial network fragmentation and mitochondrial dysfunction in prion diseases, in this study we investigated the expression of mitochondrial fusion-regulating proteins, OPA1, MFN1, and MFN2. We infected C57 mice by intracerebral injection of the RML scrapie agent and studied RML-infected brain tissues at the terminal stage of prion disease. Western blotting results showed that the OPA1 protein in cerebral cortex, medulla, and cerebellum of RML-infected mice was markedly reduced compared with age-matched wild-type (WT) mice, while OPA1 protein levels in the thalamus and hippocampus were comparable between the RML-infected and WT mice (Fig. 1a). Brain MFN1 and MFN2 protein levels in the five regions were unaffected by prion infection (Fig. 1a). Then we further observed the distribution of OPA1 in the brain by IHC. Compared with the number of large and deep-stained cells and stain intensity in the age-matched WT mice, OPA1-specific signals in the cortex, medulla, and cerebellum regions of the RML-infected mice were markedly smaller and weaker and were associated with most serious lesions in these regions of the brain (plaques or vacuoles) but not in the thalamus and hippocampus (Fig. 1b).

In the in vitro prion model, the level of OPA1 in PrP106–126-treated primary neurons started to decrease at 6 h and remained low for 24 h, while the levels of MFN1 and MFN2 showed no significant difference between the infected and control cultures during the 24-h observation period (Fig. 1c). Taken together, OPA1 is downregulated in prion disease models in vivo and in vitro.

OPA1 participates in regulation of mitochondrial network morphology in in vitro models of prion diseases

The mitochondrial morphology changes through fusion and fission, which are regulated by mitochondrial fusion/fission proteins including OPA1 and DRP1. We next asked whether OPA1 mediates PrP106–126-induced abnormal mitochondrial morphology. We observed mitochondria morphology of neuron cells with suppressed or overexpressed OPA1 and PrP106–126 treatment. First, we transiently transfected neuron cells with OPA1 siRNA and OPA1 overexpression plasmid and determined the OPA1 protein level by western blotting 48 h after transfection. The level of OPA1 in OPA1-silenced neurons was reduced by about 65% and in OPA1-overexpressed neurons it was increased by about 1.8-fold (Fig. 2a), compared with untransfected controls.

Next, we expressed the primary neurons with mito-GFP, a green fluorescent protein that specifically targets the mitochondrial matrix, for the observation of mitochondria morphology. At 48 h, the primary neurons were incubated with 150 μM PrP106–126 for 12 h and then examined by fluorescence microscopy. PrP106–126-treated primary neurons showed severely fragmented network with small and round mitochondria (Fig. 2b), in comparison to untreated control neurons with the classical mitochondrial network of filamentous and tubular mitochondria. The percentage of PrP106–126-treated neurons with fragmented mitochondria was significantly increased to about 75% in comparison to <10% in untreated control neurons (Fig. 2c). Furthermore, compared to untreated control neurons, the length of mitochondria was significantly decreased in PrP106–126-treated neurons (Fig. 2d).

To further investigate the role of OPA1 in PrP106–126-induced mitochondrial network fragmentation, primary neurons were transiently transfected with OPA1 siRNA or OPA1 overexpression plasmid, both with mito-GFP. In OPA1 siRNA-transfected neurons, most cells showed fragmented network with short and round mitochondria and the length of mitochondria was significantly decreased compared with untransfected, untreated control neurons, similar to PrP106–126-treated neurons (Fig. 2b–d). OPA1 overexpression did not alter mitochondrial network morphology but significantly inhibited PrP106–126-induced mitochondrial network fragmentation and significantly increased the length of mitochondria, showing <30% short and round mitochondria compared with PrP106–126-treated, untransfected neurons (Fig. 2b–d). Thus these results revealed that OPA1 is an important factor in PrP106–126-induced mitochondrial network fragmentation and preserves mitochondria morphology. Silencing of OPA1 aggravates mitochondrial network fragmentation, whereas overexpression of OPA1 rescues mitochondrial network morphology in the in vitro model of prion diseases.

OPA1 controls mitochondrial cristae remodeling in prion disease models

Next, we asked whether OPA1 mediates PrP106–126-induced abnormal cristae ultrastructure. Mitochondrial ultrastructure in prion disease models in vivo and in vitro were observed by electron microscopy. Mitochondria were classified by the number of cristae or swelling into the following categories based on the number of cristae or mitochondria swelling: Class I (more than four cristae), Class II (two to three cristae), Class III (no or one cristae), Class A (dense matrix), and Class B (swollen mitochondria with hypodense matrix) according to Del Dotto et al. (Fig. 3a). In WT mice, brain cortex, medulla, and cerebellum had approximately 80% of mitochondria belonging to Class I and >95% of Class A (Fig. 3b–f). On the contrary, in RML-infected mice, mitochondria of these regions of brain displayed abnormal ultrastructure, with approximately 60–80% damaged mitochondria.
characterized as markedly shorter mitochondria, reduced cristae number, and swelling (Fig. 3b–f). These findings indicated mitochondrial cristae remodeling in the in vivo prion disease model.

Next, we observed mitochondrial ultrastructure in PrP<sup>106–126</sup>-treated primary neurons. Consistent with the in vivo results, the prion peptide severely damaged mitochondria, with decreased mitochondrial length and increased fragmented mitochondria with about 81% Class III and 95% Class B mitochondria (Fig. 3g–k). We also observed that mitochondrial ultrastructure of OPA1-silenced neurons was similar to the prion peptide-treated cells, showing only 9% Class I and Class A mitochondria (Fig. 3g–k). Damaged mitochondrial ultrastructure in PrP<sup>106–126</sup>-treated primary neurons, the percentage of fragmented mitochondria, and the length of mitochondria were markedly alleviated by overexpression of OPA1, which rescued mitochondrial cristae to 68% Class I and 15% Class III and the percentage of Class A mitochondria to 70% in the in vitro prion model (Fig. 3g–k). Thus we demonstrated that OPA1 is an important factor in PrP<sup>106–126</sup>-induced mitochondrial cristae remodeling. Silencing OPA1 aggravates mitochondrial cristae damage, and overexpression of OPA1 alleviates cristae ultrastructure damage in the in vitro prion model.
Overexpression of OPA1 ameliorates PrP^{106–126}-induced mitochondrial dysfunction

We further determined whether OPA1 could affect PrP^{106–126}-induced change of mitochondrial function in the in vitro prion model. Maintaining a normal ADP/ATP ratio and ATP level is essential for cell and tissue structure and function.
Mitochondrial function was assessed after incubation with 150 μM PrP<sub>106–126</sub> for 12 h. We found that the intracellular ATP level was decreased to 50% and the ADP/ATP ratio increased by twofold, relative to the untreated control neurons (Fig. 4a, b). Similar results were observed in OPA1-suppressed neurons (Fig. 4a, b). However, OPA1 overexpression prevented prion-induced ATP loss and the increase in ADP/ATP ratio (Fig. 4a, b).

Mitochondrial membrane potential (MMP) is also a key maker of mitochondrial function. Thus we assessed mitochondrial function by the JC-1 MMP assay. In concert with the above findings, after treatment with PrP<sub>106–126</sub>, OPA1 siRNA-transfected neurons displayed increased green fluorescence (JC-1 monomer form) and decreased red fluorescence (JC-1 aggregate form) (Fig. 4c, d), indicating low MMP values and thus mitochondrial dysfunction compared with untreated control neurons. OPA1 knockdown significantly aggravated MMP alteration by the prion peptide, whereas the overexpression of OPA1 alleviated the effect of the prion peptide on MMP (Fig. 4c, d).

In summary, these results indicated that OPA1 is vital in maintaining mitochondrial function; OPA1 overexpression alleviated PrP<sub>106–126</sub>-induced mitochondrial dysfunction.

**Overexpression of OPA1 alleviates PrP<sub>106–126</sub>-induced mtDNA depletion**

To further explore the effects of prion infection on mtDNA, we measured mtDNA number. It has been previously reported that the ratio of mtDNA to nDNA represents relative mitochondria content<sup>25,26</sup>. The mtDNA copy number in RML-infected C57 mice decreased by approximately 40%, compared to WT mice brain (Fig. 5a). Similarly, we observed that PrP<sub>106–126</sub>-treated primary neurons contain about 50% of mtDNA copy number of untreated control neurons (Fig. 5b). Concordantly, similar data were found in OPA1 siRNA-transfected neurons, which had about 40% mtDNA of untreated control neurons, suggesting that OPA1 is a crucial factor in maintaining mtDNA (Fig. 5b). We further investigated whether overexpression of OPA1 can alleviate mtDNA loss in PrP<sub>106–126</sub>-treated primary neurons (Fig. 5b). OPA1 overexpression blocked PrP<sub>106–126</sub>-induced mtDNA loss; the mtDNA/nDNA ratio in OPA1-overexpressed primary neurons was 80% of that in the control neurons, compared with twofold in the prion-treated WT neurons. In summary, these results indicate that OPA1 is a crucial factor in mtDNA depletion in prion diseases. OPA1 overexpression alleviated PrP<sub>106–126</sub>-induced mtDNA depletion.

**OPA1 overexpression protects from PrP<sub>106–126</sub>-induced neuron apoptosis**

The accumulation of mitochondrial cristae remodeling and mitochondrial dysfunction results in cell death. As one of the cellular functions of OPA1 was preventing apoptosis by controlling the release of cytochrome c<sup>20</sup>, we further tested the role of OPA1 in PrP<sub>106–126</sub>-induced cell death. First, we measured the cell viability by the CCK-8 assay in PrP<sub>106–126</sub>-treated primary neurons. Compared with the untreated control neurons, the cell viability of PrP<sub>106–126</sub>-treated primary neurons decreased to about 60% (Fig. 6a). However, the percentage of surviving neurons relative to PrP<sub>106–126</sub>-treated primary neurons significantly increased from 60% to 80% in neurons with overexpressed OPA1 (Fig. 6a).

It is well known that cytochrome c proteins act downstream in the mitochondrial apoptotic pathway. Then, to further confirm the function of OPA1 in PrP<sub>106–126</sub>-induced cell death, we overexpressed OPA1 protein in primary neurons, treated with 150 μM PrP<sub>106–126</sub> for 24 h. Primary neurons and RML-infected mouse brains were fractionated to mitochondrial and cytosolic extracts and mitochondrial and cytosol cytochrome c protein levels were measured by western blot analysis (Fig. 6b–e). We found that mitochondrial cytochrome c was severely decreased and cytosol cytochrome c was severely increased in RML-infected mouse brain, suggesting release of cytochrome c, compared with the WT mouse brain (Fig. 6b, c). Consistent with the
in vivo results, cytochrome c release also occurred in PrP106–126-treated primary neurons (Fig. 6e, f). Overexpression of OPA1 significantly inhibited the release of cytochrome c (Fig. 6e, f).

Activation of caspase 3 is important in apoptotic cell death in many chronic neurodegenerative diseases. We studied whether overexpression of OPA1 repressed the activation of caspase 3. The levels of cleaved caspase 3 in the brains of terminal-stage RML-infected mice was significantly increased, compared with WT mice (Fig. 6f). Similarly, prion peptide treatment of neuronal cells also led to caspase 3 activation and cell death (Fig. 6a, g).
Overexpression of OPA1 significantly reduced caspase 3 activation induced by PrP106–126 (Fig. 6g).

In summary, these results indicated that OPA1 overexpression prevented PrP106–126-induced neuron apoptosis.

Discussion

Prion diseases are a family of fatal neurodegenerative disorders, with long incubation periods and characteristic spongiform changes in the brain associated with the progressive loss of neuronal cells and their function. The mechanisms of neurodegeneration remain unclear and effective therapeutic targets have not been discovered despite decades of research by scientists worldwide. In this study, we found that OPA1 protein, which regulates IMM events, is downregulated in in vitro and in vivo prion disease models, and overexpression of OPA1 blocked prion-induced mitochondrial network fragmentation and mitochondrial dysfunction, loss of mtDNA, and neuronal apoptosis, suggesting that OPA1 could be an effective therapeutic target for the treatment of early-stage prion diseases.

We demonstrated that OPA1 expression significantly decreased in cerebral cortex, medulla, and cerebellum of RML-infected mice and PrP106–126-treated primary neurons, similar to the findings in the brains of 139A-, ME7-, 263K- and S15-infected mice. In addition, downregulated OPA1 has been reported in other neurodegenerative diseases models, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease (HD), and retinal ischemia–reperfusion-related diseases. Mitochondria with suppressed OPA1 were incapable of fusion. OPA1-knockdown mouse embryonic fibroblasts exhibited mitochondrial network fragmentation, abnormal ultrastructure, less mitochondrial cristae number, mitochondrial swelling, and decreased mtDNA copy numbers. Re-expression of any OPA1 isoform ameliorated cristae abnormality, mtDNA abundance, and energetic efficiency. Similarly, we showed that overexpression of OPA1 prevented mitochondrial network fragmentation, cristae remodeling, and mtDNA depletion in PrP106–126-treated primary neurons.

Maintaining normal ATP level and MMP is critical for neuronal survival. In neurodegenerative diseases, mitochondrial network fragmentation and disruption of cristae structure, as a result of reduced ATP levels and dissipated MMP, are responsible for neuronal dysfunction. Our observation of marked reduction in ATP and MMP loss in the in vitro prion model suggests neuronal dysfunction. Depletion of OPA1 resulted in ATP and MMP loss and induced OPA1-dependent mitochondrial fragmentation and cristae damage. Not surprisingly, we found that overexpression of OPA1 abolished the effects of prion on the ATP level and MMP, as well as mitochondrial structure damage by the prion peptide. In addition, it was reported that overexpression of OPA1 improved respiratory chain efficiency in two mouse models of oxidative phosphorylation complex I and IV deficiency. We...
will further study the impact of OPA1 overexpression on respiratory chain in prion disease models.

It has been documented that increases of several apoptosis factors including cleaved caspase 3 have been found in the brain tissues of hamsters infected with 263K and mice infected with 139A or ME7. We also found a significant increase of cleaved caspase 3 and release of cytochrome c in RML-infected C57 mouse brains, compared with the age-matched control. Intriguingly, it was reported that OPA1-dependent mitochondrial cristae remodeling controls apoptotic independently from mitochondrial fusion, and OPA1 protects cells from apoptosis by maintaining cristae junctions tight and cristae density and controlling the release of cytochrome c. Mild overexpression of OPA1 prevented muscular atrophy, heart and brain ischemia, and liver apoptosis by OPA1-dependent mitochondrial cristae remodeling. In a mouse HD model, overexpression of OPA1, but not the overexpression of the fusion factor MFN1, reversed the increased susceptibility to cell death inherent in the HD model, suggesting that enhanced fusion alone is not sufficient to inhibit apoptosis, further highlighting the crucial role of OPA1-controlled cristae remodeling in apoptosis. Furthermore, mitochondrial fragmentation may be essential for cytochrome c redistribution and mitochondrial dynamics, and the delicate balance between fusion and...
fission is very important in the timely execution of apoptosis.\(^{9,41}\) Inhibition of DRP1-mediated fission or excess mitochondrial fusion induced by overexpression of OPA1, MFN1, and/or MFN2 diminishes or delays apoptotic stimuli-induced mitochondrial fragmentation, cytochrome c release, and cell death, whereas overexpression of DRP1 or downregulation of OPA1, MFN1, or MFN2 aggravates apoptosis.\(^{42}\) Published and our current study results support the notion that OPA1 inhibits apoptosis through enhancing mitochondria fusion and maintaining mitochondria cristae integrity.

Our work indicates that overexpression of OPA1 alleviates mitochondrial damage in prion diseases by preventing mitochondrial network fragmentation, disorganization of cristae structure, mtDNA loss, mitochondrial dysfunction, and cell death. OPA1 is a potential therapeutic target in prion diseases.

Acknowledgements
This work was supported by National Key Research and Development Program (Project No. 2017YFC1200500, No. 2017YFD0501600) and 948 projects (2014-S9).

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Pruiner, S. B., Telling, G., Cohen, F. E. & Dearmond, S. J. Prion diseases of humans and animals. Seno. Vis. 7, 159–173 (1996).
2. Claudio, S. & Nikunj, S. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol. Med. 17, 14–24 (2011).
3. Hur, K. et al. The pathogenic mechanisms of prion diseases. Mech. Ageing Dev. 123, 1657–1667 (2002).
4. Hu, W., Rosenberg, R. N. & Stuve, O. Prion proteins: a biological role beyond prion disease. Acta Neurol. Scand. 116, 75–82 (2010).
5. Forkoni, G. et al. Neurotoxicity of a prion protein fragment. Nature 362, 543–546 (1993).
6. Selvaggi, C. et al. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Biochem. Biophys. Res. Commun. 194, 1380–1386 (1993).
7. Gu, Y., Fujoka, H., Mishra, R. S., Li, R. & Singh, N. Prion peptide: 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PEP. J. Biol. Chem. 277, 2275–2286 (2002).
8. Gao, J. et al. Abnormalities of mitochondrial dynamics in neurodegenerative diseases. Antioxidants 6, E25 (2017).
9. Cleland, M. M. & Youle, R. J. Mitochondrial Dynamics and Apoptosis. (Springer, Netherlands, 2011).
10. Yoo, S. M. & Jung, Y. K. A molecular approach to mitophagy and mitochondrial dynamics. Mol. Cell. 41, 18–26 (2018).
11. Hidenori, O. et al. MF is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J. Cell Biol. 191, 1141–1158 (2010).
12. Losón, O. C., Song, Z., Chen, H. & Chan, D. C. Fst1, MF, MID49, and MID51 mediate Drp1 recruitment in mitochondrial fission. Mol. Biol. Cell 24, 659–667 (2013).
13. Chang, C. R. & Blackstone, C. Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann. NY Acad. Sci. 1201, 14–39 (2010).
14. Ishihara, N., Eura, Y. & Mishara, K. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J. Cell Sci. 117, 6535–6546 (2004).
15. Koshiba, T. et al. Structural basis of mitochondrial tethering by mitofusin complexes. Science 305, 858–862 (2004).
16. Sara, C., Olga, M. D. B., Barbara, D. Z. & Luca, S. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc. Natl Acad. Sci. USA 101, 15927–15932 (2004).
17. Elachouri, G. et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res. 21, 12–20 (2011).
18. Coglilati, S. et al. Mitochondrial cristae shape determines respiratory chain superstructures and respiratory efficiency. Cell 155, 160–171 (2013).
19. Frezza, C. et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fission. Cell 126, 177–189 (2006).
20. Olichon, A. et al. Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 278, 7743–7746 (2003).
21. Song, Z. et al. REST alleviates neurotoxic prion peptide-induced synaptic abnormalities, neurofilament degeneration and neuronal death partially via LRP6-mediated Wnt-β-catenin signaling. Oncotarget 7, 12035–12052 (2016).
22. Yang, X. D. et al. Aberrant alterations of mitochondrial factors Drp1 and Opa1 in the brains of sciapie experiment rodents. J. Mol. Neurosci. 61, 1–11 (2017).
23. Li, C. et al. DL1-dependent mitochondrial fragmentation and redistribution mediate prion-associated mitochondrial dysfunction and neuronal death. Aging Cell https://doi.org/10.1111/acel.12693 (2018).
24. Del Dotto, V. et al. OPA1 isoforms in the hierarchical organization of mitochondrial functions. Cell Rep. 19, 2557–2571 (2017).
25. Lee, H., Smith, S. B. & Yoon, Y. The short variant of the mitochondrial dynamin OPA1 maintains mitochondrial energetics and cristae structure. J. Biol. Chem. 292, 7115 (2017).
26. Chen, H. et al. Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141, 280–289 (2010).
27. Wang, X. et al. Impaired balance of mitochondria fusion and fission in Alzheimer disease. J. Neurosci. 29, 9000–9013 (2009).
28. Santos, D., Esteves, A. R., Silva, D. F., Januário, C. & Cardoso, S. M. The impact of mitochondrial fusion and fission modulation in sporadic Parkinson’s disease. Mol. Neurobiol. 52, 573–586 (2015).
29. Uzubat, S. et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease implications for selective neuronal damage. Hum. Mol. Genet. 20, 1438–1455 (2011).
30. Sun, Y., Xue, W., Song, Z., Huang, K. & Zheng, L. Restoration of Opa1-long isoform inhibits retinal injury-induced neurodegeneration. J. Mol. Med. 94, 335–346 (2016).
31. Costa, V. et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli. EMBO Mol. Med. 2, 490–503 (2010).
32. Tug, G. et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 27, 433–446 (2008).
33. Gomes, L. C., Di, B. G. & Scorrano, L. Essential amino acids and glutamine regulate induction of mitochondrial elongation during autophagy. Cell Cycle 10, 2635–2639 (2011).
34. Song, Z., Chen, H., Fieret, M., Alexander, C. & Chan, D. C. OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L. J. Cell Biol. 178, 749–755 (2007).
35. Wang, X. et al. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson’s disease. Aging Cell 10, 807–823 (2011).
36. Mančak, M., Kandimalla, R., Fry, D., Sesaki, H. & Reddy, P. H. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum. Mol. Genet. 25, 5148–5166 (2016).
37. Civiletto, G. et al. Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models. Cell Metab. 21, 845–854 (2015).
38. Varanita, T. et al. The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage. Cell Metab. 21, 834–844 (2015).
39. Scorrano, L. et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev. Cell 2, 55–67 (2002).
40. Yamaguchi, R. et al. Opa1-mediated cristae opening is Bax/Bak and BH3 dependent, required for apoptosis, and independent of Bak oligomerization. Mol. Cell 31, 557–569 (2008).
41. Aouacheria, A. et al. Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins. Neurochem. Int. 109, 141–161 (2017).
42. Rie, S., Shigeomi, S. & Yoshihide, T. Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis. J. Biol. Chem. 279, 52726–52734 (2004).